Fracture risk in metastatic breast cancer patients treated with CDK 4/6 inhibitors and endocrine therapy [0.03%]
CDK4/6抑制剂联合内分泌治疗转移性乳腺癌患者的骨折风险
Rebecca Pedersini,Laura Moretti,Marta Laganà et al.
Rebecca Pedersini et al.
Purpose: Investigate skeletal morbidity (SM) in metastatic breast cancer (MBC) patients undergoing CDK4/6 inhibitors (CDK4/6is) and endocrine therapy (ET). ...
Real-world outcomes of reduced-dose versus standard-dose antibody drug conjugates in metastatic breast cancer: a retrospective cohort study [0.03%]
剂量减少的抗体药物偶联物与标准剂量抗体药物偶联物在转移性乳腺癌中真实世界结局的差异：一项回顾性队列研究
Nickolas Stabellini,Jasskiran Kaur,Cynthia Owusu et al.
Nickolas Stabellini et al.
Purpose: To evaluate whether reduced doses (RD) of trastuzumab deruxtecan (T-DXd) or sacituzumab govitecan (SG) provide similar outcomes to the approved standard doses (SD) in metastatic breast cancer (mBC). ...
Translational and real-world evidence of trastuzumab biosimilar CT-P6 plus pertuzumab in neoadjuvant HER2-positive early breast cancer [0.03%]
曲妥珠单抗类似物CT-P6联合帕妥珠单抗新辅助治疗HER2阳性早期乳腺癌的转化和真实世界证据
José Luis Alonso-Romero,Jerónimo Martínez-García,Raúl Carrillo-Vicente et al.
José Luis Alonso-Romero et al.
Background: Data on neoadjuvant treatment with trastuzumab biosimilars, particularly CT-P6, in combination with pertuzumab, are limited. This study evaluates the efficacy, tolerability, and immunogenicity of CT-P6 plus pe...
Observational Study
Breast cancer research and treatment. 2026 Jan 20;215(2):60. DOI:10.1007/s10549-026-07895-8 2026
Trends in postmastectomy radiotherapy for early and locally advanced breast cancer in Switzerland: a population-based cross-sectional and longitudinal analysis [0.03%]
瑞士乳腺癌术后放疗趋势：基于人群的横断面和纵向分析
Marcel Blum,Sonja Marion Koch,Mohsen Mousavi et al.
Marcel Blum et al.
Purpose: Postmastectomy radiotherapy (PMRT) reduces locoregional recurrence and improves survival in high-risk breast cancer (BC), yet its real-world use remains variable. Population-based data on PMRT utilization and gui...
Updated systematic review and meta-analysis: taking the next step in physical activity behavioral interventions for post-treatment breast cancer survivors [0.03%]
更新后的系统评价和meta分析：乳腺癌术后幸存者的身体活动行为干预的下一步措施
Brianna N Leitzelar,Alana R Willis,Sarah N Price et al.
Brianna N Leitzelar et al.
Purpose: To provide an updated review of the literature on physical activity (PA) intervention studies, their characteristics, and their effect size estimates for PA behavior change among early post-treatment breast cance...
Outcomes of patients with de novo oligometastatic breast cancer treated with curative intent at a single institution [0.03%]
单中心以根治为目的治疗de novo寡转移乳腺癌患者的疗效分析
Emily L Chen,Hillary Heiling,Tianyu Li et al.
Emily L Chen et al.
Purpose: De novo oligometastatic breast cancer (OMBC) is often defined as up to five metastases in two or fewer organs at presentation. Studies have suggested favorable outcomes for patients with OMBC; however, management...
Anti-HER2 treatment in everyday practice: how we treat older women with breast cancer differently [0.03%]
抗HER2治疗的日常实践：我们如何区别对待老年乳腺癌患者
S Hjorth,K F Vandraas,C B Trewin-Nybråten et al.
S Hjorth et al.
Purpose: Targeted therapies have improved survival in human epidermal growth factor receptor 2 positive breast cancer (HER2 + BC). However, patients over 75 years of age are often excluded from clinical trials of anti-HER...
Prognosis and endocrine therapy efficacy in early breast cancer with estrogen receptor low expression [0.03%]
雌激素受体低表达早期乳腺癌的预后和内分泌治疗疗效研究
Sihua Liu,Beidi Du,Mengmeng Zhang et al.
Sihua Liu et al.
Purpose: To investigate the prognosis and endocrine therapy (ET) efficacy in patients with estrogen receptor (ER)-low breast cancer. Methods: ...
Inhibition of GPX4 induces the death of p53-mutant triple-negative breast cancer cells [0.03%]
GPX4抑酶诱导三阴性乳腺癌细胞死亡
William M Tahaney,Amanda Lanier,Jing Qian et al.
William M Tahaney et al.
Background: Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer characterized by high rates of tumor protein 53 (TP53) mutation and with limited targeted therapies. Despite being clinically adva...
Risk of second non-breast primary cancer in Chinese breast cancer patients with germline BRCA1/2 pathogenic variants [0.03%]
携带BRCA1/2致病突变的中国乳腺癌患者第二原发癌症风险研究
Jiaming Liu,Futao Chu,Lu Yao et al.
Jiaming Liu et al.
Purpose: The risk of second non-breast primary cancer in Chinese women with breast cancer who carry germline BRCA1/2 pathogenic variants (PVs) is largely unknown. ...